Skip to main content

Advertisement

Table 2 PABAK – OS – 3-level interpretation

From: Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis

Drug Class Drug Proportion observed agreement Minor discrepancy Major discrepancy PABAK-OS 95%CI of PABAK-OS
NNRTI Etravirine 0.99 18 1 0.98 (0.96 - 1.01)
NRTI Abacavir 0.98 20 0 0.98 (0.96 - 1.01)
  Didanosine 0.99 19 0 0.98 (0.96 - 1.01)
  Lamivudine 1.00 1 0 1.00 (0.97 - 1.03)
  Stavudine 0.99 16 0 0.99 (0.96 - 1.01)
  Tenofovir 1.00 5 0 1.00 (0.97 - 1.02)
  Zidovudine 0.98 21 0 0.98 (0.95 - 1.01)
PI Atazanavir/r 1.00 5 0 1.00 (0.97 - 1.02)
  Darunavir/r 1.00 0 0 1.00 (0.97 - 1.03)
  Lopinavir/r 1.00 2 0 1.00 (0.97 - 1.03)
  Saquinavir/r 1.00 2 0 1.00 (0.97 - 1.03)
  Tipranavir/r 1.00 4 0 1.00 (0.97 - 1.02)